0IRF.IL

Evotec SE [0IRF.IL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0IRF.IL Stock Summary

Earnings have grown 21.59% per last year.

The Moving Average Convergence Divergence (MACD) for 0IRF.IL recently turned positive (within last 10 days).

Top 10 Correlated ETFs

0IRF.IL

Top 10 Correlated Stocks

0IRF.IL

In the News

0IRF.IL Financial details

Company Rating

Market Cap

2.44B

Income

-128.36M

Revenue

781.13M

Book val./share

Cash/share

Dividend

Dividend %

Employees

5.07K

Optionable

Shortable

Yes

Earnings

24 Apr 2024

P/E

-24.51

Forward P/E

PEG

1.57

P/S

4.03

P/B

2.76

P/C

P/FCF

-19.34

Quick Ratio

1.93

Current Ratio

2.16

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.72

EPS next Y

EPS next Q

EPS this Y

-176.15%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

14.89%

Revenue Q/Q

15.27%

EPS Q/Q

160.66%

SMA20

12.82%

SMA50

-19.54%

SMA100

-21.34%

Inst Own

Inst Trans

ROA

-6%

ROE

-11%

ROC

-0.01%

Gross Margin

25%

Oper. Margin

-3%

Profit Margin

-16%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

12.54-24.44

52W High

-69.71%

52W Low

-39.42%

RSI

61.91

Rel Volume

0.15

Avg Volume

319.05K

Volume

46.93K

Perf Week

12.02%

Perf Month

12.89%

Perf Quarter

1.25%

Perf Half Y

3.27%

Beta

1.08289

Volatility

0.21%, 0.66%

Prev Close

-2.94%

Price

7.27

Change

-3.45%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 319.05K
Market Capitalization 2.44B
Employee 5.07K
CEO Dr. Werner Lanthaler M.B.A., MPA, Ph.D.
Headquarters Hamburg,DE
IPO Date 2008-05-06
Website https://www.evotec.com

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.